Ranbaxy Laboratories, Inc.

Aurigene Oncology Limited

Vinayak Vasantrao Khairnar

Venkata Poornapragnacharyulu Palle

Abhijit Ray

Sarala Balachandran

Nidhi Gupta

Muralidhara Ramachandra

Sunanda Ghosh Dastidar

Dinesh Chikkanna

Sonali Rudra

Leena Khare Satyam

Lalit Kumar Baregama

Sunanda Ghose Dastidar

Mandadapu Raghuramaiah

Lalitha Vijaykrishnan

Manohar Salla

Atul Kondaskar

Mandadapu Raghu Ramaiah

Ritu Agarwal

The present invention relates to substituted alkynylene compounds represented by the compounds of formula (I), pharmaceutically acceptable salts and stereoisomers thereof. The present invention further provides the therapeutic uses of the compounds of formula (I) as anti-cancer agents.

Substituted alkynylene compounds as anticancer agents

The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4/PDE type 7 inhibitors. Compounds disclosed herein having the structure of Formula 1: can be useful in the treatment, prevention, inhibition or suppression of CNS diseases, for example, multiple sclerosis; various pathological conditions such as diseases affecting the immune system, including AIDS, rejection of transplant, auto-immune disorders such as T-cell related diseases, for example, rheumatoid arthritis; inflammatory diseases such as respiratory inflammation diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) and other inflammatory diseases including but not limited to psoriasis, shock, atopic dermatitis, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis; gastrointestinal inflammation diseases such as Crohn's disease, colitis, pancreatitis as well as different types of cancers including leukaemia; especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type 4, PDE type 7 and dual PDE type 4/PDE type 7 inhibitors are provided. 

Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors

The present invention relates to phosphodiesterase (PDE) type IV selective inhibitors. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type IV selective inhibitors are provided. Prepared compounds correspond to structure XIV Formula (XIV). 

Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors

Growing community of inventors

Nashik, India

Vinayak Vasantrao Khairnar